^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

LATS kinase inhibitor

Related drugs:
2years
Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib. (PubMed, Sci Rep)
Taken together, our results suggest that LATS could be one of the key factors contributing to the rapid proliferation, reduced apoptosis, and IM resistance of CML cells. Targeting LATS could be a promising treatment to enhance the therapeutic effect of a conventional BCR/ABL tyrosine kinase inhibitor such as IM.
Journal
|
LATS1 (Large Tumor Suppressor Kinase 1) • LATS2 (Large Tumor Suppressor Kinase 2)
|
imatinib